PYXS

Company Overview — What Does Pyxis Oncology, Inc. Do?

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology, Inc. (PYXS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Lara S. Sullivan and employs approximately 60 people. With a market capitalization of $92M, PYXS is one of the notable companies in the Healthcare sector.

Pyxis Oncology, Inc. (PYXS) Stock Rating — Reduce (April 2026)

As of April 2026, Pyxis Oncology, Inc. receives a Reduce rating with a composite score of 29.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.PYXS ranks #3,690 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Pyxis Oncology, Inc. ranks #607 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

PYXS Stock Price and 52-Week Range

Pyxis Oncology, Inc. (PYXS) currently trades at $1.70. The stock gained $0.09 (5.6%) in the most recent trading session. The 52-week high for PYXS is $5.55, which means the stock is currently trading -69.4% from its annual peak. The 52-week low is $0.83, putting the stock 104.0% above its annual trough. Recent trading volume was 728K shares, suggesting relatively thin trading activity.

Is PYXS Overvalued or Undervalued? — Valuation Analysis

Pyxis Oncology, Inc. (PYXS) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.72x, versus the sector average of 2.75x. The price-to-sales ratio is 32.53x, compared to 1.66x for the average Healthcare stock.

At current multiples, Pyxis Oncology, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Pyxis Oncology, Inc. Profitability — ROE, Margins, and Quality Score

Pyxis Oncology, Inc. (PYXS) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -154.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -90.4% versus the sector average of -33.1%.

On a margin basis, Pyxis Oncology, Inc. reports gross margins of 82.8%, compared to 71.5% for the sector. The operating margin is -700.4% (sector: -66.1%). Net profit margin stands at -650.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -3.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

PYXS Debt, Balance Sheet, and Financial Health

Pyxis Oncology, Inc. has a debt-to-equity ratio of 71.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.41x, indicating strong short-term liquidity. Total debt on the balance sheet is $43,000. Cash and equivalents stand at $9M.

PYXS has a beta of 1.29, meaning it is more volatile than the broader market — a $10,000 investment in PYXS would be expected to move 28.9% more than the S&P 500 on any given day. The stability factor score for Pyxis Oncology, Inc. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Pyxis Oncology, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Pyxis Oncology, Inc. reported revenue of $3M and earnings per share (EPS) of $-1.28. Net income for the quarter was $-83M. Gross margin was 82.8%. Operating income came in at $-90M.

In FY 2025, Pyxis Oncology, Inc. reported revenue of $14M and earnings per share (EPS) of $-1.28. Net income for the quarter was $-80M. Gross margin was 82.8%. Revenue grew -14.2% year-over-year compared to FY 2024. Operating income came in at $-84M.

In Q3 2025, Pyxis Oncology, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.35. Net income for the quarter was $-22M. Operating income came in at $-23M.

In Q2 2025, Pyxis Oncology, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.30. Net income for the quarter was $-18M. Operating income came in at $-20M.

Over the past 8 quarters, Pyxis Oncology, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $3M. Investors analyzing PYXS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

PYXS Dividend Yield and Income Analysis

Pyxis Oncology, Inc. (PYXS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

PYXS Momentum and Technical Analysis Profile

Pyxis Oncology, Inc. (PYXS) has a momentum factor score of 48/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

PYXS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Pyxis Oncology, Inc. (PYXS) ranks #607 out of 838 stocks based on the Blank Capital composite score. This places PYXS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing PYXS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PYXS vs S&P 500 (SPY) comparison to assess how Pyxis Oncology, Inc. stacks up against the broader market across all factor dimensions.

PYXS Next Earnings Date

No upcoming earnings date has been announced for Pyxis Oncology, Inc. (PYXS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy PYXS? — Investment Thesis Summary

The quantitative profile for Pyxis Oncology, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. High volatility (stability score 19/100) increases portfolio risk.

In summary, Pyxis Oncology, Inc. (PYXS) earns a Reduce rating with a composite score of 29.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PYXS stock.

Related Resources for PYXS Investors

Explore more research and tools: PYXS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare PYXS head-to-head with peers: PYXS vs AZN, PYXS vs SLGL, PYXS vs VMD.